Sumitomo Mitsui Trust Group Inc. Has $39.20 Million Position in The Clorox Company $CLX

Sumitomo Mitsui Trust Group Inc. boosted its stake in shares of The Clorox Company (NYSE:CLX) by 2.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 326,436 shares of the company’s stock after buying an additional 7,568 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned approximately 0.26% of Clorox worth $39,195,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Hsbc Holdings PLC lifted its stake in shares of Clorox by 118.8% in the 1st quarter. Hsbc Holdings PLC now owns 1,085,661 shares of the company’s stock valued at $159,699,000 after purchasing an additional 589,544 shares during the period. Robeco Institutional Asset Management B.V. raised its stake in Clorox by 101.8% during the 2nd quarter. Robeco Institutional Asset Management B.V. now owns 1,083,723 shares of the company’s stock worth $130,123,000 after buying an additional 546,761 shares during the period. AQR Capital Management LLC raised its stake in Clorox by 412.1% during the 1st quarter. AQR Capital Management LLC now owns 598,758 shares of the company’s stock worth $88,167,000 after buying an additional 481,846 shares during the period. Goldman Sachs Group Inc. raised its stake in Clorox by 147.6% during the 1st quarter. Goldman Sachs Group Inc. now owns 707,005 shares of the company’s stock worth $104,107,000 after buying an additional 421,453 shares during the period. Finally, Nuveen LLC acquired a new stake in Clorox in the 1st quarter valued at $42,300,000. 78.53% of the stock is owned by institutional investors and hedge funds.

Clorox Trading Down 0.3%

Clorox stock opened at $115.21 on Wednesday. The stock has a market cap of $14.03 billion, a P/E ratio of 17.67, a PEG ratio of 0.96 and a beta of 0.52. The Clorox Company has a fifty-two week low of $114.55 and a fifty-two week high of $171.37. The firm’s fifty day moving average price is $120.99 and its 200-day moving average price is $126.50. The company has a debt-to-equity ratio of 5.15, a quick ratio of 0.57 and a current ratio of 0.84.

Clorox (NYSE:CLX) last released its quarterly earnings results on Thursday, July 31st. The company reported $2.87 earnings per share for the quarter, topping the consensus estimate of $2.24 by $0.63. The firm had revenue of $1.99 billion for the quarter, compared to analysts’ expectations of $1.94 billion. Clorox had a net margin of 11.40% and a return on equity of 377.86%. The business’s quarterly revenue was up 4.5% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.82 earnings per share. Clorox has set its FY 2026 guidance at 5.950-6.30 EPS. Equities research analysts forecast that The Clorox Company will post 7.15 earnings per share for the current fiscal year.

Clorox Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Thursday, November 6th. Investors of record on Wednesday, October 22nd will be paid a $1.24 dividend. This represents a $4.96 dividend on an annualized basis and a yield of 4.3%. The ex-dividend date of this dividend is Wednesday, October 22nd. Clorox’s dividend payout ratio is currently 76.07%.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on CLX shares. Citigroup reduced their price target on shares of Clorox from $135.00 to $130.00 and set a “neutral” rating for the company in a research report on Wednesday, October 8th. Zacks Research raised Clorox from a “strong sell” rating to a “hold” rating in a report on Monday, September 29th. Deutsche Bank Aktiengesellschaft decreased their price objective on Clorox from $135.00 to $128.00 and set a “hold” rating for the company in a report on Monday, October 13th. Barclays decreased their price objective on Clorox from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Tuesday, September 30th. Finally, Morgan Stanley reduced their target price on Clorox from $150.00 to $137.00 and set an “equal weight” rating for the company in a report on Friday, August 1st. One research analyst has rated the stock with a Buy rating, twelve have issued a Hold rating and four have assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $130.20.

Insider Activity

In other news, COO Eric H. Reynolds sold 15,041 shares of the firm’s stock in a transaction dated Thursday, September 4th. The stock was sold at an average price of $123.78, for a total transaction of $1,861,774.98. Following the transaction, the chief operating officer directly owned 54,221 shares of the company’s stock, valued at approximately $6,711,475.38. This trade represents a 21.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 0.63% of the company’s stock.

Clorox Profile

The Clorox Company manufactures and markets consumer and professional products worldwide. It operates through four segments: Health and Wellness, Household, Lifestyle, and International. The Health and Wellness segment offers cleaning products, such as laundry additives and home care products primarily under the Clorox, Clorox2, Scentiva, Pine-Sol, Liquid-Plumr, Tilex, and Formula 409 brands; professional cleaning and disinfecting products under the CloroxPro and Clorox Healthcare brands; professional food service products under the Hidden Valley brand; and vitamins, minerals and supplement products under the RenewLife, Natural Vitality, NeoCell, and Rainbow Light brands in the United States.